Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson´s disease
Ver/ Abrir
Registro completo
Mostrar el registro completo DCAutoría
Brown, Emmeline E.; Blauwendraat, Cornelis; Trinh, Joanne; Rizig, Mie; Nalls, Mike A.; Leveille, Etienne; Ruskey, Jennifer A.; Jonvik, Hallgeir; Tan, Manuela M.X.; Bandres-Ciga, Sara; Hassin-Baer, Sharon; Brockmann, Kathrin; Infante Ceberio, Jon
Fecha
2021-01Derechos
© <2021>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
Publicado en
Neurobiology of Aging, Volume 97, January 2021, Pages 148.e17-148.e24
Editorial
Elsevier
Enlace a la publicación
Palabras clave
Parkinson’s disease
Genetic modifiers
Parkinsonism
Leucine-rich repeat kinase 2
Resumen/Abstract
The LRRK2 gene has rare (p.G2019S) and common risk variants for Parkinson?s disease (PD). DNM3 has
previously been reported as a genetic modifier of the age at onset in PD patients carrying the LRRK2
p.G2019S mutation. We analyzed this effect in a new cohort of LRRK2 p.G2019S heterozygotes (n ¼ 724)
and meta-analyzed our data with previously published data (n ¼ 754). VAMP4 is in close proximity to
DNM3, and was associated with PD in a recent study, so it is possible that variants in this gene may be
important. We also analyzed the effect of VAMP4 rs11578699 on LRRK2 penetrance. Our analysis of DNM3
in previously unpublished data does not show an effect on age at onset in LRRK2 p.G2019S carriers;
however, the inter-study heterogeneity may indicate ethnic or population-specific effects of DNM3. There
was no evidence for linkage disequilibrium between DNM3 and VAMP4. Analysis of sporadic patients
stratified by the risk variant LRRK2 rs10878226 indicates a possible interaction between common vari-
ation in LRRK2 and VAMP4 in disease risk
Colecciones a las que pertenece
- D22 Artículos [1093]